PMID- 16156690
OWN - NLM
STAT- MEDLINE
DCOM- 20051129
LR  - 20181201
IS  - 1175-3277 (Print)
IS  - 1175-3277 (Linking)
VI  - 5
IP  - 5
DP  - 2005
TI  - Fondaparinux sodium: a review of its use in the treatment of acute venous 
      thromboembolism.
PG  - 335-46
AB  - Fondaparinux sodium (fondaparinux) is a synthetic sulfated pentasaccharide 
      anticoagulant developed from the antithrombin binding moiety of heparin. Through 
      the activation of antithrombin it inhibits Factor Xa, the activation of thrombin, 
      and the subsequent coagulation cascade. Fondaparinux is approved in Europe and 
      the US for the treatment of acute venous thromboembolism (VTE), including both 
      deep vein thrombosis (DVT) and pulmonary embolism (PE), when used in conjunction 
      with warfarin. In phase III clinical trials, subcutaneous fondaparinux was 
      noninferior to subcutaneous enoxaparin or intravenous unfractionated heparin 
      (UFH) in the prevention of recurrent symptomatic VTE in patients with acute DVT 
      and PE, respectively, and equally well tolerated. It thus provides a valuable 
      alternative to UFH and low-molecular weight heparins in the treatment of acute 
      VTE, particularly in the outpatient setting.
FAU - Robinson, Dean M
AU  - Robinson DM
AD  - Adis International Inc., Yardley, Pennsylvania 19067, USA. demail@adis.com
FAU - Wellington, Keri
AU  - Wellington K
LA  - eng
PT  - Journal Article
PL  - New Zealand
TA  - Am J Cardiovasc Drugs
JT  - American journal of cardiovascular drugs : drugs, devices, and other 
      interventions
JID - 100967755
RN  - 0 (Anticoagulants)
RN  - 0 (Polysaccharides)
RN  - 9000-94-6 (Antithrombin III)
RN  - J177FOW5JL (Fondaparinux)
SB  - IM
MH  - Acute Disease
MH  - Anticoagulants/*therapeutic use
MH  - Antithrombin III/*therapeutic use
MH  - Clinical Trials as Topic
MH  - Fondaparinux
MH  - Humans
MH  - Polysaccharides/adverse effects/pharmacokinetics/pharmacology/*therapeutic use
MH  - Venous Thrombosis/*drug therapy
EDAT- 2005/09/15 09:00
MHDA- 2005/12/13 09:00
CRDT- 2005/09/15 09:00
PHST- 2005/09/15 09:00 [pubmed]
PHST- 2005/12/13 09:00 [medline]
PHST- 2005/09/15 09:00 [entrez]
AID - 557 [pii]
AID - 10.2165/00129784-200505050-00007 [doi]
PST - ppublish
SO  - Am J Cardiovasc Drugs. 2005;5(5):335-46. doi: 10.2165/00129784-200505050-00007.